Confirmatory Study of the Efficacy and Safety of the Fixed-dose Combination Atorvastatin / Fenofibrate Versus Atorvastatin on the Lipid Profile of Patients With Type 2 Diabetes (T2D) and Dyslipidaemia (DLP).

Phase IIIb, randomized, longitudinal, prospective, multicenter study to evaluate the efficacy and safety of the fixed-dose combination atorvastatin / fenofibrate versus atorvastatin on the lipid profile of patients with type 2 diabetes and dyslipidemia.

开始日期2022-02-15

申办/合作机构

Laboratorios Silanes SA de CV

NCT00664859 / Completed临床2/3期

A 12-Month, Open-Label, Extension Study of the Safety and Efficacy of LCP-AtorFen in Subjects With Dyslipidemia

The current study is designed to test the long-term (12-month) safety and efficacy of LCP-AtorFen, a combination of atorvastatin and fenofibrate, in patients with dyslipidemia

开始日期2007-10-01

申办/合作机构

Veloxis Pharmaceuticals A/S

NCT00504829 / Completed临床2期

A 12-Week, Multi-Center, Double-Blind, Randomized, Parallel-Group Study, Followed by a 12 Month Extension Study, of the Efficacy and Safety of LCP-AtorFen in Subjects With Dyslipidemia

The current study is designed to test the efficacy, safety and tolerability of LCP-AtorFen, a combination of atorvastatin and fenofibrate.

开始日期2007-07-01

申办/合作机构

Veloxis Pharmaceuticals A/S

100 项与阿托伐他汀钙/非诺贝特相关的临床结果

登录后查看更多信息

100 项与阿托伐他汀钙/非诺贝特相关的转化医学

登录后查看更多信息

100 项与阿托伐他汀钙/非诺贝特相关的专利（医药）

登录后查看更多信息

项与阿托伐他汀钙/非诺贝特相关的新闻（医药）

2007-11-20

·BioSpace

LifeCycle Pharma Completes Patient Enrollment in Phase II Clinical Trial of LCP-AtorFen for the Treatment of Mixed Dyslipidemia, Initiates 52-Week Open Label Extension Study

H0RSHOLM, Denmark--(BUSINESS WIRE)--LifeCycle Pharma A/S (OMX: LCP) (the “Company” or “LCP”), an emerging specialty pharmaceutical company, today announced that it has completed patient enrollment in its Phase II clinical trial of LCP-AtorFen for the treatment of mixed dyslipidemia, which commenced in July 2007 to compare LCP-AtorFen, the Company’s fixed-dose combination product candidate of atorvastatin and lowest dose fenofibrate, with Lipitor® (40 mg atorvastatin calcium tablets) and Tricor® (145mg fenofibrate tablets). In addition, the Company announced that it has initiated a 52-week, open-label extension study in order to capture additional safety and efficacy data on the use of LCP AtorFen in patients with mixed dyslipidemia.

合作

100 项与阿托伐他汀钙/非诺贝特相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB05769

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
血脂障碍	临床3期	美国	Veloxis Pharmaceuticals A/S	2007-10-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00664859 (CTgov)	临床2/3期	血脂障碍	140	LCP-AtorFen (LCP-AtorFen 40/100mg)	選鬱願積醖齋遞憲鑰醖(壓壓遞遞衊構艱衊鏇壓) = 願鹽壓網遞醖壓製鹽積醖顧憲衊糧築齋繭顧廠 (襯簾遞鬱糧獵繭艱廠衊, 簾簾鬱鹽鬱衊艱遞壓膚 ~ 衊淵觸顧繭膚鏇廠選簾) 更多	-	2020-03-24
				Atorvastatin (Atorvastatin 40 mg)	選鬱願積醖齋遞憲鑰醖(壓壓遞遞衊構艱衊鏇壓) = 襯構構鏇餘鏇夢夢糧簾醖顧憲衊糧築齋繭顧廠 (襯簾遞鬱糧獵繭艱廠衊, 顧遞襯觸遞憲窪獵衊網 ~ 窪築鏇廠構醖觸廠窪獵) 更多
NCT00504829 (CTgov)	临床2期	血脂障碍	220	LCP-AtorFen (LCP-AtorFen 40/100mg)	憲鑰衊艱艱網糧積艱積(衊衊選製衊繭憲願觸鏇) = 齋範觸簾網繭窪膚願糧淵築鹽積膚襯窪願構構 (齋鏇願齋醖鹹鬱壓夢選, 選壓襯蓋鹽選鹹鏇膚顧 ~ 蓋遞齋壓齋網餘製觸襯) 更多	-	2020-02-05
				Atorvastatin (Atorvastatin 40mg)	憲鑰衊艱艱網糧積艱積(衊衊選製衊繭憲願觸鏇) = 餘觸範淵餘繭鹹觸糧顧淵築鹽積膚襯窪願構構 (齋鏇願齋醖鹹鬱壓夢選, 鬱製觸願積憲壓夢衊壓 ~ 選廠顧鹽簾鹹糧襯獵遞) 更多
NCT01974297 \| NCT00504829 (Pubmed \| Med Lett Drugs Ther)	临床2期	血脂障碍	220	Atorvastatin/fenofibrate FDC	簾鏇醖築淵窪網廠鬱鏇(鹽餘遞鹽製醖鑰範鬱顧) = 製鹹範醖憲觸壓製衊觸糧餘鑰膚餘窪選艱鏇窪 (鬱齋鏇鏇艱鹽窪鏇壓築 ) 更多	-	2009-12-01
				Atorvastatin 40 mg	簾鏇醖築淵窪網廠鬱鏇(鹽餘遞鹽製醖鑰範鬱顧) = 積膚觸齋範繭餘選築獵糧餘鑰膚餘窪選艱鏇窪 (鬱齋鏇鏇艱鹽窪鏇壓築 ) 更多